Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium acts similar to calcium and is preferentially taken up in osteoblastic tissue while the unabsorbed isotope is excreted in the urine the first 2 to 3 days following injection, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Generic Strontium Chloride Sr-89 Injection USP can be used in combination with opiate based drugs like Oxycotin®, Morphine, Percocet® as well as cancer therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with Sr-89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.

Generic Strontium-89 injection is a pure beta emitter, and selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from bone lesions. The presence of bone metastases should be confirmed prior to therapy.

When blastic osseous metastases are present, significantly enhanced localization of the radiopharmaceutical will occur with corresponding higher doses to the metastases compared with normal bones and other organs. Although responses can vary, pain relief typically beginning 7 to 20 days after injection and lasts for months. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STUDIES:

PRELIMINARY APPLICATION OF STRONTIUM 89 FOR THE TREATMENT OF BONE METASTASES FROM PROSTATE CANCER

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Dec;27(6):1251-4. Zhao W, Deng H, Jie P, Qing C, Zhang X.

Department of Nuclear Medicine, West China Hospital of Sichuan
University, Chengdu 610041, China.
Abstract

Bone metastases are a major problem in the clinical management of patients with prostate cancer. Despite the use of analgesic for the relief of such pain, the outcomes are not often satisfactory.

Strontium-89 (89Sr) is a pure beta-emitting radioisotope to be avidly concentrated in the areas of high osteoblastic activity. The aim of this study was to evaluate the efficacy of 89Sr in the therapy for bone metastases of prostate carcinoma. 116 patients received intravenous injection of 89Sr at the dose of 3mCi (111MBq). All patients underwent physical examination and Karnofsky’s Performance Score (KPS) evaluation before and after administration; the analgesic effects were evaluated by scores of pain. The complete response (CR) was defined as scores of pain > 75%; no response (NR) was defined as scores of pain < 25% the remaining was partial response (PR). The changes of bone metastases were screened by CT, MRI and 99mTc-MDP bone scintigraphy according to the standards of WHO. After the treatment with 89Sr, the total response rate was 80.2%. In the 116 cases, 21 cases (18.1%) displayed complete response and 72 cases (62.1%) displayed partial response, but 23 cases (19.2%) showed no response.

The mean score on Karnfsky’s performance status (KPS) was 20.0% higher. About 1/3 cases exhibited an obvious decrease in the number of metastases, and some foci disappeared. Thirteen cases (12%) showed a greater decrease in prostate-specific antigen (PSA) value. 89Sr chloride is an effective and safe therapy of the bone metastases from prostate cancer.

PMID: 21374974 [PubMed]
1. Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer.
Zhao W, Deng H, Jie P, Qing C, Zhang X.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Dec;27(6):1251-4. Chinese.
PMID: 21374974 [PubMed – in process]
Related citations
2. Tumoricidal effect of strontium-89.
Yoshimura M, Saito K, Park J, Akata S, Koizumi K, Tokuue K, Kakizaki D.
Clin Nucl Med. 2011 Apr;36(4):296-9. No abstract available.
PMID: 21368605 [PubMed – in process]
Related citations
3. Therapeutic nuclear medicine in pediatric malignancy.
Schmidt M, Baum RP, Simon T, Howman-Giles R.
Q J Nucl Med Mol Imaging. 2010 Aug;54(4):411-28. Review.
PMID: 20823809 [PubMed – indexed for MEDLINE]
Related citations
4. Complete regression of multiple painful bone metastases from hepatocellular carcinoma after administration of strontium-89 chloride.
Suzawa N, Yamakado K, Takaki H, Nakatsuka A, Takeda K.
Ann Nucl Med. 2010 Oct;24(8):617-20. Epub 2010 May 21.
PMID: 20490724 [PubMed – indexed for MEDLINE]
Related citations
5. [Strontium-89 for bone metastases from prostate cancer: an update].
Zhao WW, Xie P, Deng HF.
Zhonghua Nan Ke Xue. 2010 Mar;16(3):269-72. Review. Chinese.
PMID: 20369560 [PubMed – indexed for MEDLINE]
Related citations
6. The Open Prostate Cancer Journal, 2009, 2, 54-58
1876-8229/09 2009 Bentham Open
Open Access
Strontium 89 Combined with Gemcitabine in Androgen-Resistant Prostate
Cancer: Results of a Phase I-II Study
Keizman Daniel, Maimon Natalie, Stefansky Irena, Sarid David, Levita
Moshe, Vexler Akiva and
Ben-Yosef Rami* The Open Prostate Cancer Journal, 2009, 2, 54-58
7. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.
Paes FM, Serafini AN.
Semin Nucl Med. 2010 Mar;40(2):89-104. Review.
PMID: 20113678 [PubMed – indexed for MEDLINE]
Related citations
9. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ, Hernandez-McClain J, Henary H.
Am J Clin Oncol. 2008 Dec;31(6):532-8.
PMID: 19060583 [PubMed – indexed for MEDLINE]
Related citations
11. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
Zhonghua Nan Ke Xue. 2008 Sep;14(9):819-22. Chinese.
PMID: 18998467 [PubMed – indexed for MEDLINE]
Related citations
12. The use of radioisotopes for palliation of metastatic bone pain.
Gkialas I, Iordanidou L, Galanakis I, Giannopoulos S.
J BUON. 2008 Apr-Jun;13(2):177-83. Review.
PMID: 18555462 [PubMed – indexed for MEDLINE]
Related citations
13. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
Logothetis CJ, Navone NM, Lin SH.
Clin Cancer Res. 2008 Mar 15;14(6):1599-602. Review.
PMID: 18347159 [PubMed – indexed for MEDLINE] Free Article
Related citations
14. Current trials using bone-targeting agents in prostate cancer.
Tu SM, Lin SH.
Cancer J. 2008 Jan-Feb;14(1):35-9. Review. Erratum in: Cancer J. 2008
May-Jun;14(3):199.
PMID: 18303481 [PubMed – indexed for MEDLINE]
Related citations

Source: http://www.ncbi.nlm.nih.gov/pubmed/21374974

September 7, 2016

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the closing of an exclusive license and option agreement for a FDA approved generic drug, Strontium Chloride (“SR89”).

 

“We are very excited about the potential for this drug and look forward to bringing it to market as quickly as possible, delivering significant value to all stakeholders, including current and future patients. The revenue we hope to realize will be a significant milestone for us and substantially derisks our business. However, over and above the near term revenue, we are particularly enthusiastic about the opportunities for growth to increase the potential revenue exponentially.”  – Denis Corin CEO Q BioMed Inc.

Social media & sharing icons powered by UltimatelySocial